Literature DB >> 26267327

Genetics of Apparently Sporadic Pheochromocytoma and Paraganglioma in a Chinese Population.

C H Lee1, C Y Y Cheung1, W S Chow1, Y C Woo1, C Y Yeung1, B H H Lang2, C H Y Fong1, K H M Kwok1, S P L Chen3, C M Mak3, K C B Tan1, K S L Lam1.   

Abstract

Identification of germline mutation in patients with apparently sporadic pheochromocytomas and paragangliomas is crucial. Clinical indicators, which include young age, bilateral or multifocal, extra-adrenal, malignant, or recurrent tumors, predict the likelihood of harboring germline mutation in Caucasian subjects. However, data on the prevalence of germline mutation, as well as the applicability of these clinical indicators in Chinese, are lacking. We conducted a cross-sectional study at a single endocrine tertiary referral center in Hong Kong. Subjects with pheochromocytomas and paragangliomas were evaluated for the presence of germline mutations involving 10 susceptibility genes, which included NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, TMEM 127, MAX, and FH genes. Clinical indicators were assessed for their association with the presence of germline mutations. Germline mutations, 2 being novel, were found in 24.4% of the 41 Chinese subjects recruited and 11.4% among those with apparently sporadic presentation. The increasing number of the afore-mentioned clinical indicators significantly correlated with the likelihood of harboring germline mutation in one of the 10 susceptibility genes. (r=0.757, p=0.026). The presence of 2 or more clinical indicators should prompt genetic testing for germline mutations in Chinese subjects. In conclusion, our study confirmed that a significant proportion of Chinese subjects with apparently sporadic pheochromocytoma and paraganglioma harbored germline mutations and these clinical indicators identified from Caucasians series were also applicable in Chinese subjects. This information will be of clinical relevance in the design of appropriate genetic screening strategies in Chinese populations. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26267327     DOI: 10.1055/s-0035-1555955

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  3 in total

1.  Routine genetic screening with a multi-gene panel in patients with pheochromocytomas.

Authors:  Emilia Sbardella; Treena Cranston; Andrea M Isidori; Brian Shine; Aparna Pal; Bahram Jafar-Mohammadi; Greg Sadler; Radu Mihai; Ashley B Grossman
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

Review 2.  When should genetic testing be performed in patients with neuroendocrine tumours?

Authors:  Triona O'Shea; Maralyn Druce
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Identification of a novel SDHB c.563 T > C mutation responsible for Paraganglioma syndrome and genetic analysis of the SDHB gene in China: a case report.

Authors:  Heye Chen; Wei Yao; Qing He; Xuefang Yu; Bo Bian
Journal:  BMC Med Genet       Date:  2020-05-27       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.